[go: up one dir, main page]

NO960811L - Karbosykliske og heterosykliske kinolinkarboksylsyrer med kondenserte ringer som kan anvendes som immunresponsundertrykkende midler - Google Patents

Karbosykliske og heterosykliske kinolinkarboksylsyrer med kondenserte ringer som kan anvendes som immunresponsundertrykkende midler

Info

Publication number
NO960811L
NO960811L NO960811A NO960811A NO960811L NO 960811 L NO960811 L NO 960811L NO 960811 A NO960811 A NO 960811A NO 960811 A NO960811 A NO 960811A NO 960811 L NO960811 L NO 960811L
Authority
NO
Norway
Prior art keywords
carbocyclic
compounds
suppressants
immune response
carboxylic acids
Prior art date
Application number
NO960811A
Other languages
English (en)
Other versions
NO960811D0 (no
Inventor
Ronald Louis Magolda
William John Pitts
Irina Cipora Jacobson
Carl Henry Behrens
Michael James Orwat
Douglas Guy Batt
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of NO960811D0 publication Critical patent/NO960811D0/no
Publication of NO960811L publication Critical patent/NO960811L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Denne oppfinnelsen vedrører. karbosykliske og heterosykliske kino-linkarboksylsyreforbindelser med kon-densert ring, valgt fra forbindelser. med formlene. eller farmasøytisk akseptable salter. derav, farmasøytiske preparater som om-fatter slike forbindelser, og frem-gangsmåter for anvendelse av slike forbindelser til behandlingen og/eller forhindringen av organtransplantasjons-avvisning, graft-versus-host-sykdom, autoimmunsykdommer, kroniske betennel-sessykdommer, inkludert, men ikke be-grenset til, psoriasis og reumatoid artritt, og kreft hos et pattedyr.
NO960811A 1993-08-31 1996-02-28 Karbosykliske og heterosykliske kinolinkarboksylsyrer med kondenserte ringer som kan anvendes som immunresponsundertrykkende midler NO960811L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/114,712 US5428040A (en) 1993-08-31 1993-08-31 Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
PCT/US1994/009463 WO1995006640A1 (en) 1993-08-31 1994-08-26 Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents

Publications (2)

Publication Number Publication Date
NO960811D0 NO960811D0 (no) 1996-02-28
NO960811L true NO960811L (no) 1996-04-29

Family

ID=22356972

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960811A NO960811L (no) 1993-08-31 1996-02-28 Karbosykliske og heterosykliske kinolinkarboksylsyrer med kondenserte ringer som kan anvendes som immunresponsundertrykkende midler

Country Status (19)

Country Link
US (4) US5428040A (no)
EP (1) EP0716652A1 (no)
JP (1) JPH09501442A (no)
KR (1) KR960704851A (no)
AU (1) AU690140B2 (no)
CA (1) CA2170349A1 (no)
CZ (1) CZ51696A3 (no)
FI (1) FI960933A0 (no)
HR (1) HRP940484A2 (no)
HU (1) HUT74585A (no)
IL (1) IL110821A (no)
NO (1) NO960811L (no)
NZ (1) NZ273156A (no)
PL (1) PL313981A1 (no)
RU (1) RU2133740C1 (no)
SK (1) SK27096A3 (no)
TW (1) TW342390B (no)
WO (1) WO1995006640A1 (no)
ZA (1) ZA946658B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20050260201A1 (en) * 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
CA2150235A1 (en) * 1993-09-28 1995-04-06 Fumio Suzuki A novel tetracyclic compound
US5681958A (en) * 1995-06-07 1997-10-28 Shaman Pharmaceuticals, Inc. Cryptolepine analogs with hypoglycemic activity
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
IL129096A0 (en) * 1996-09-23 2000-02-17 Univ Rutgers Substituted heterocycles as anti-tumor agents
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US20050031611A1 (en) * 1998-05-08 2005-02-10 Beth Israel Deaconess Medical Center Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
GB9825632D0 (en) * 1998-11-23 1999-01-13 Novartis Ag Organic compounds
US7323471B1 (en) 1999-08-13 2008-01-29 Dor Biopharma, Inc. Topical azathioprine for the treatment of oral autoimmune diseases
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
PL392652A1 (pl) * 2001-05-16 2010-12-06 Novartis Ag Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację
EP2279742A3 (en) * 2001-10-05 2011-04-20 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
IL161430A0 (en) * 2001-10-19 2004-09-27 Pharma Mar Sa Pharmaceutical compositions containing ecteinascidin 743
JP4628675B2 (ja) * 2001-11-14 2011-02-09 ラトガーズ，ザ ステイト ユニバーシティ 可溶化トポイソメラーゼ毒
WO2003051289A2 (en) * 2001-11-14 2003-06-26 Rutgers, The State University Solubilized topoisomerase poison agents
EP1453812B1 (en) 2001-11-14 2008-08-20 Rutgers, The State University Cytotoxic agents
ATE390923T1 (de) * 2001-11-14 2008-04-15 Univ Rutgers Topoisomerase-giftmittel
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
AU2003261354A1 (en) * 2002-08-02 2004-02-23 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
US6992089B2 (en) * 2002-08-09 2006-01-31 Rutgers, The University Of New Jersey Nitro and amino substituted topoisomerase agents
US6989387B2 (en) * 2002-08-09 2006-01-24 Rutgers, The State University Of New Jersey Nitro and amino substituted topoisomerase agents
AU2003265405A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted heterocycles as topoisomerase i targeting agents
WO2004044174A2 (en) * 2002-11-12 2004-05-27 Rutgers, The State University Topoisomerase-targeting agents
FR2856687B1 (fr) * 2003-06-25 2005-09-16 Servier Lab Nouveaux derives de benzo[a]pyrano[3,2-h]acridin-7-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
RU2257915C2 (ru) * 2003-10-17 2005-08-10 Государственное учреждение Московский областной научно-исследовательский институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения обострений рассеянного склероза
BRPI0514974A (pt) 2004-09-07 2008-07-01 Wyeth Corp composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto
AU2005294575B2 (en) 2004-10-04 2011-11-24 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2007002867A1 (en) 2005-06-28 2007-01-04 Cv Therapeutics, Inc. Abca1 elevating compounds
EP1948243A2 (en) * 2005-11-02 2008-07-30 Aeris Therapeutics, Inc. Polycation-polyanion complexes, compositions and methods of use thereof
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
MX2008014828A (es) * 2006-05-22 2009-02-06 Combinatorx Inc Metodos y composiciones para el tratamiento de enfermedades o condiciones asociadas con niveles incrementados de proteina c-reactiva, interleucina-6 o interferon-gamma.
WO2008079139A1 (en) * 2006-12-27 2008-07-03 Cv Therapeutics, Inc. Abca1 elevating compounds
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
TW200942549A (en) 2007-12-17 2009-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
KR20100121601A (ko) * 2007-12-17 2010-11-18 콤비네이토릭스, 인코포레이티드 면역염증성 질환의 치료를 위한 치료요법
JP5684719B2 (ja) 2008-12-05 2015-03-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
US9562051B2 (en) 2009-03-06 2017-02-07 Rutgers, The State University Of New Jersey Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer
WO2010127363A1 (en) 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
MX339146B (es) * 2009-12-15 2016-05-13 Novartis Ag Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
CA2899206C (en) 2013-01-24 2019-07-09 Transderm, Inc. Compositions for transdermal delivery of mtor inhibitors
WO2015077535A2 (en) 2013-11-22 2015-05-28 Genzyme Corporation Novel methods for treating neurodegenerative diseases
US11091498B2 (en) 2016-04-04 2021-08-17 Rutgers, The State University Of New Jersey Topoisomerase poisons
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
AR127618A1 (es) 2021-11-29 2024-02-14 Bayer Ag Dihidropiranopiridinas sustituidas, sales o n-óxidos de las mismas y su uso como sustancias herbicidamente activas

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
US4847381A (en) * 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US4968701A (en) * 1988-04-26 1990-11-06 E. I. Du Pont De Nemours And Company 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids
US4918077A (en) * 1989-01-25 1990-04-17 E. I. Du Pont De Nemours & Co., Inc. 3-phenyl-5,6-dihydrobenz(c)acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents
JP2515415B2 (ja) * 1990-02-28 1996-07-10 株式会社東芝 半導体素子の外部リ―ドの成型方法
US5304554A (en) * 1990-04-27 1994-04-19 Emory University 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation
US5135934A (en) * 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5225418A (en) * 1991-12-17 1993-07-06 Du Pont Merck Pharmaceutical Company 5H-(1,2)benzisothiazolo[2,3-a]quinoline-5-ones and analogs as antiinflammatory agents
US5179100A (en) * 1992-03-09 1993-01-12 Hoechst-Roussel Pharmaceuticals Inc. 4,5-dihydropyrazolo[3,4-a]acridines
DE69319859T2 (de) * 1992-04-24 1998-12-17 Kyowa Hakko Kogyo K.K., Tokio/Tokyo Neue tetracyclische verbindungen
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents

Also Published As

Publication number Publication date
NO960811D0 (no) 1996-02-28
IL110821A0 (en) 1994-11-11
US5874441A (en) 1999-02-23
RU2133740C1 (ru) 1999-07-27
HU9600501D0 (en) 1996-04-29
TW342390B (en) 1998-10-11
HUT74585A (en) 1997-01-28
SK27096A3 (en) 1996-12-04
FI960933A7 (fi) 1996-02-28
NZ273156A (en) 1997-06-24
WO1995006640A1 (en) 1995-03-09
US5428040A (en) 1995-06-27
US5639759A (en) 1997-06-17
AU690140B2 (en) 1998-04-23
PL313981A1 (en) 1996-08-05
FI960933A0 (fi) 1996-02-28
IL110821A (en) 1997-04-15
AU7635894A (en) 1995-03-22
US6110910A (en) 2000-08-29
HRP940484A2 (en) 1997-02-28
CZ51696A3 (en) 1996-06-12
EP0716652A1 (en) 1996-06-19
JPH09501442A (ja) 1997-02-10
CA2170349A1 (en) 1995-03-09
KR960704851A (ko) 1996-10-09
ZA946658B (en) 1996-02-29

Similar Documents

Publication Publication Date Title
NO960811L (no) Karbosykliske og heterosykliske kinolinkarboksylsyrer med kondenserte ringer som kan anvendes som immunresponsundertrykkende midler
Tanner et al. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1. 3 channel blocker HsTX1 [R14A] and its PEGylated analog
CN104136436B (zh) 抗纤维化的化合物及其用途
UA39166C2 (uk) Похідні n-гідроксисечовини, що є інгібіторами ліпоксигенази у ссавців, спосіб їх одержання і спосіб інгібування ліпоксигенази у ссавців
HU229864B1 (en) Use of amide compounds for the preparation of medicaments
DE69231252D1 (de) Substituierte Salizylsäure zur Behandlung von Autoimmunkrankheiten
CL2023002393A1 (es) Anticuerpos anti-cd30l y usos de estos
EA200100872A1 (ru) Композиция валдекоксиба
NO177785C (no) Analogifremgangsmåter for fremstilling av terapeutisk aktive alkoksy-4(1H)-pyridonderivater
ATE232102T1 (de) Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthrose
EP1206265A4 (en) SRC-KINASE INHIBITING COMPOUNDS
ES8706668A1 (es) Un procedimiento para la preparacion de derivados de piperidina.
MY106038A (en) 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents.
DK0529568T3 (da) Nye oralt aktive elastaseinhibitorer
DK472184D0 (da) 2-amino-5-hydroxy-4-methylpyrimidin-derivater og farmeceutiske praeparater indeholdende disse
ES8603870A1 (es) Un procedimiento para la preparacion de derivados de 2,2'-iminobisetanol.
CN108938642A (zh) 免疫相关和炎性疾病的治疗
Tanner et al. Targeting KCa1. 1 channels with a scorpion venom peptide for the therapy of rat models of rheumatoid arthritis
AU2019387473A1 (en) Composition and method for treating dementia
AR010984A1 (es) Nuevos esteres de la pleuromutilina, y el acido 1-azabiciclo-4- carbanilcarbanico; procedimiento para su preparacion y composicionesfarmaceuticas que los contienen.
DK0451654T3 (da) Anvendelse af N-alkylerede 1,4-dihydropyridin-dicarboxylsyreestere som lægemidler, nye forbindelser og fremgangsmåder til deres fremstilling
EP0434057A3 (en) Indolocarbazole derivatives, processes for their preparation and their use
CA2377254A1 (en) Non-malignant disease treatment with ras antagonists
DE69717969D1 (de) Substituierte n-methyl-n-(4-(piperidin-1-yl)-2-arylbutyl)-benzamide zur behandlung von allergischen erkrankungen
SUTNICK et al. Systemic lupus erythematosus and hypertension without renal insufficiency